Who owns BAQSIMI?
BAQSIMI is owned by Amphastar (the United States, NASDAQ: AMPH), which has owned the brand since 2023.[1]
Evidence: Amphastar Pharmaceuticals, Inc. Annual Report on Form 10-K filed 2026-02-26, SEC EDGAR, 26 February 2026. Verified from filings; last checked .
Key facts
- Current owner
- Amphastar Pharmaceuticals, Inc. verified
- Owned since
- Owner HQ
- 🇺🇸 United States, Rancho Cucamonga
- Origin
- 🇺🇸 United States
- Category
- Healthcare & pharma › Drug makers › Pharmaceuticals
- Parent ticker
- NASDAQ: AMPH
- Last verified
- · 1 sources
About BAQSIMI
BAQSIMI is a dry nasal spray of glucagon 3mg for emergency treatment of severe hypoglycemia in people with diabetes aged four and over, described in Amphastar's 10-K as the first and only nasally administered glucagon. Amphastar bought it from Eli Lilly under an asset purchase agreement dated 21 April 2023 and completed the acquisition in June 2023. It is sold in the US and 26 other markets.
Ownership timeline of BAQSIMI
Where BAQSIMI sits in Amphastar
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Amphastar ownership tree →
See the full Amphastar brand portfolio (4) →
Other brands owned by Amphastar
Amphastar controls 4 brands on Brandtree, 4 of them in healthcare & pharma.
Also in healthcare & pharma
Other brands in pharmaceuticals, and who owns them
The 27 brands in pharmaceuticals on Brandtree belong to 10 owners. The largest is Teva, with 4; Amphastar has 4.
About the owner: Amphastar
Amphastar is a publicly listed company headquartered in Rancho Cucamonga, United States, founded in 1996. Brandtree records 4 brands under its control, and it is listed as NASDAQ: AMPH.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company based in Rancho Cucamonga, California. It incorporated in California in 1996 and reincorporated in Delaware in 2004. Its 10-K for 2025 says it develops, makes and sells technically challenging generic and proprietary injectable, inhalation and intranasal products and active pharmaceutical ingredients, with net revenues of $719.9 million in 2025.
🇺🇸 BAQSIMI and other American brands
Brandtree records a controlling owner for 2,549 brands that began in the United States. 478 of them (19%) are now controlled by a company headquartered in another country; BAQSIMI is not one of them.
Frequently asked questions
Who is the parent company of BAQSIMI?
The parent company of BAQSIMI is Amphastar, a publicly listed company headquartered in the United States.
Is BAQSIMI American?
Yes. BAQSIMI originated in the United States and its owner, Amphastar, is also headquartered in the United States.
Since when has Amphastar owned BAQSIMI?
Amphastar has owned BAQSIMI since 2023.
Is BAQSIMI still owned by Amphastar?
Yes. As of 18 October 2026, BAQSIMI is still owned by Amphastar. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Amphastar Pharmaceuticals, Inc. Annual Report on Form 10-K filed 2026-02-26 — SEC EDGAR, SEC Form 10-K, published 26 February 2026; retrieved 18 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.